SCHEMBL5568407

SCHEMBL5568407

CN[C@@H](C(C)C)C(O)C(=O)OC(C)(C)C

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 1/20 0.45
CA1 P00915 1/20 0.38
CA2 P00918 1/20 0.38
CA7 P43166 1/20 0.38
CA12 O43570 1/20 0.35
CA14 Q9ULX7 1/20 0.35
DGAT1 O75907 1/20 0.34
NOS1 P29475 2/20 0.33
NOS3 P29474 1/20 0.33
NOS2 P35228 1/20 0.33
CTSK P43235 2/20 0.33
CTSS P25774 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.31
KMT2A Q03164 2/20 0.31
HTRA1 Q92743 1/20 0.31
LMNA P02545 1/20 0.31
CTSL P07711 1/20 0.31
CTSB P07858 1/20 0.31
ABCB1 P08183 1/20 0.30
MEN1 O00255 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5565244 0.83 CTSK (0.38) CYP2D6CA1CA2CA7CA12
SCHEMBL5565293 0.81 CA12 (0.36) CYP2D6CA1CA2CA7CA12
SCHEMBL4671964 0.80 CA1 (0.39) CYP2D6CA1CA2CA7CA12
SCHEMBL11855010 0.80 CA1 (0.39) CYP2D6CA1CA2CA7CA12
SCHEMBL4671957 0.80 CA1 (0.39) CYP2D6CA1CA2CA7CA12
SCHEMBL7973604 0.77 CTSK (0.40) CYP2D6CA1CA2CA7CA12
SCHEMBL22787789 0.77 CTSK (0.40) CYP2D6CA1CA2CA7CA12
SCHEMBL7973606 0.77 CTSK (0.40) CYP2D6CA1CA2CA7CA12
SCHEMBL1845280 0.77 HTT (0.40) CYP2D6CA1CA2CA7CA12
SCHEMBL19407016 0.77 HTT (0.40) CYP2D6CA1CA2CA7CA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7312343-B2 N-benzyl-protected dialkyl acetal derivatives undergo desired aldol reaction with high diastereoselectivity using a Mukaiyama aldol reaction; intermediates in the synthesis of other products, including, e.g. Dolastatin 10 HOFFMANN-LA ROCHE INC. (US) 2007-12-25 US disclosed
EP-1756038-A1 SYNTHESIS OF AMINO-ALKOXY-HEPTANOIC ALKYL ESTER F.HOFFMANN-LA ROCHE AG (CH) 2007-02-28 EP disclosed
WO-2005118525-A1 SYNTHESIS OF AMINO-ALKOXY-HEPTANOIC ALKYL ESTER F.HOFFMANN-LA ROCHE AG (CH) 2005-12-15 WO disclosed
US-20050272665-A1 Synthesis of alpha-amino-beta-alkoxy-carboxylic acid esters F. HOFFMANN-LA ROCHE AG (CH) 2005-12-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050272665-A1 Synthesis of alpha-amino-beta-alkoxy-carboxylic acid esters ALDH7A1, BCAT1, BCAT2 CYP2D6 285/4885CA1 557/4885CA2 1831/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.